Track 06 of 9
Gut Microbiome
FMT, microbiota-based therapeutics and dysbiosis.
Microbiota therapeutics have transitioned from investigational FMT into FDA-approved live biotherapeutic products: Rebyota (RBL-2660) and Vowst (SER-109) for prevention of recurrent C. difficile infection. The track examines real-world durability, cost-effectiveness vs. fidaxomicin and bezlotoxumab, and emerging applications in IBD, hepatic encephalopathy, and ICI-refractory melanoma. Mechanistic sessions cover bile-acid signaling, short-chain fatty acid production, and engineered consortia. Diagnostic content addresses shotgun metagenomics standardization, the limits of 16S rRNA profiling, and the regulatory pathway for next-generation probiotics under FDA biologic frameworks.
Focus areas
- Vowst (SER-109) and Rebyota for recurrent C. difficile prevention
- FMT in ulcerative colitis and pouchitis: donor selection and outcomes
- Microbiota modulation of immune checkpoint inhibitor response
- Engineered consortia and defined live biotherapeutic products
- Shotgun metagenomics standardization and clinical reporting
- Bile acid–microbiome axis in cholestatic and metabolic disease
- Helicobacter pylori AMR: vonoprazan-amoxicillin and rifabutin regimens